

**Virginia Medicaid Preferred Drug List (PDL) Program:
Annual Review of PDL Phase II and Review of New Drugs and Potential New Classes
Pharmacy and Therapeutics Committee Meeting
Tuesday, April 22, 2008
10:00 a.m., 7th Floor Conference Rooms
DRAFT AGENDA**

**Welcome and Comments from
DMAS' Director**

**Patrick Finnerty,
DMAS Director**

Comments from the Chairperson

**Randy Axelrod, M.D.,
Chairman**

**Acceptance of Minutes From
October 3, 2007 P&T Meeting**

P&T Committee Members

**Review of Final Guidance Document
for Generic Drug Policy**

P&T Committee Members

Drug Class Discussions

P&T Committee Members

Review of Potential New Drug Classes

- DPP-IV Inhibitors
- Topical Antibiotics

Review of New Drugs in PDL Phase I

Antihistamines – Second Generation

- Zyrtec OTC & Zyrtec-D OTC
- Cetirizine & Cetirizine-D
- Allegra ODT

Beta Blockers

- Bystolic

Proton Pump Inhibitors

- Pantoprazole

***HMG CoA Reductase Inhibitors and
Combinations – Statins***

- Simcor

Urinary Tract Antispasmodics

- Sanctura XR

Electrolyte Depleters

- Revela

Ace Inhibitors

- Altace Tablet
- Ramipril

ACE Inhibitor/ ARB Calcium Channel Blocker

- Azor

Phase II PDL Annual Review

Oral Hypoglycemics

- Second Generation Sulfonylureas
- Alpha-Glucosidase Inhibitors
- Biguanides
- Biguanide Combination
- Meglitinides
- Thiazolidinediones
- Thiazolidinediones-Metformin
Combinations
- Thiazolidinediones-Sulfonylurea
Combinations

Leukotriene

- Leukotriene Modifiers
- Leukotriene Formation Inhibitors

Antibiotics/Anti-infective

- Second Generation Cephalosporins
- Third Generation Cephalosporins
- Second Generation Quinolones - Systemic
- Third Generation Quinolones - Systemic
- Macrolides - Adult and Pediatric
- Oral Antifungals for Onychomycosis
- Herpes Antivirals
- Influenza Antivirals
- Ketolides

Central Nervous System

- Antihyperkinesis/CNS Stimulants

Osteoporosis

- Bisphosphonates

Phase II PDL Annual Review (con't)

Analgesics

- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (*now includes Cox-2 Inhibitors*)
- Long Acting Narcotics

Miscellaneous

- Serotonin Receptor Agonists (Tryptans)

Ophthalmics

- Glaucoma Alpha-2 Adrenergic
- Glaucoma Beta-blockers
- Glaucoma Carbonic Anhydrase Inhibitors
- Glaucoma Prostaglandin Analogs
- Ophthalmic Anti-Inflammatory (NSAID)
- Ophthalmic Quinolones
- Ophthalmic Antihistamines
- Ophthalmic Mast Cell Stabilizers

Confidential Meeting

**Confidential Meeting for
P&T Committee Members,
DMAS, and FHSC Pursuant
to 42 U.S.C. § 1396r-8 to
discuss pricing information**

Criteria Discussion of New Drug Classes, Phase I New Drugs, and Phase II Drug Classes *

P&T Committee Members

Next Meeting – TBD

**Randy Axelrod, M.D.,
Chairman**

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during
Drug Class Discussions*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to PDL Phase II annual review, potential new drug classes, and specific new drugs in PDL Phase I classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase II Annual Review – April 2007 to present
- New Drugs in PDL Phase I Drug Classes – October 2006 to present
- Potential New Drug Classes – October 2006 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmavirginia.gov by **COB Tuesday, April 8, 2008.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmavirginia.gov by **COB Tuesday, April 8, 2008.**